10x Genomics (TXG) has acquired Proteintech Genomics, a division of Proteintech Group specializing in high-plex proteomic solutions, significantly enhancing its capabilities in proteomics and multiomics research. The acquisition was announced on [insert date], aiming to integrate protein analysis technologies like the Human Discovery Panel with existing single-cell and spatial biology platforms, bolstering research capabilities.
The acquisition is expected to have no meaningful impact on TXG’s near-term financial outlook, though TXG anticipates it will strengthen long-term growth prospects in the rapidly evolving proteomics market, valued at approximately $38.4 billion in 2025 and projected to exceed $97.7 billion by 2033 with a CAGR of 13.3%. TXG currently has a market capitalization of $3.7 billion.
Since the announcement, TXG’s shares rose by 4.8%, in contrast to a 20.5% decline in the industry. The overall value of TXG shares increased by 87.6% year-to-date, significantly outpacing the S&P 500, which grew by 8.4%.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
